Safety and Tolerability of Histone Deacetylase (HDAC) Inhibitors in Oncology
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Histone deacetylases (HDACs) are expressed at increased levels in cells of various malignancies, and the use of HDAC inhibitors has improved outcomes in patients with haematological malignancies (T-cell lymphomas and multiple myeloma). However, they are not as effective in solid tumours. Five agents are currently approved under various jurisdictions, namely belinostat, chidamide, panobinostat, romidepsin and vorinostat. These agents are associated with a range of class-related and agent-specific serious and/or severe adverse effects, notably myelosuppression, diarrhoea and various cardiac effects. Among the cardiac effects are ST-T segment abnormalities and QTc interval prolongation of the electrocardiogram, isolated cases of atrial fibrillation and, in rare instances, ventricular tachyarrhythmias. In order to improve the safety profile of this class of drugs as well as their efficacy in indications already approved and to further widen their indications, a large number of newer HDAC inhibitors with varying degrees of HDAC isoform selectivity have been synthesised and are currently under clinical development. Preliminary evidence from early studies suggests that they may be effective in non-haematological cancers as well when used in combination with other therapeutic modalities, but that they too appear to be associated with the above class-related adverse effects. As the database accumulates, the safety, efficacy and risk/benefit of the newer agents and their indications wi…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“KDAC inhibitors often exhibit sub-optimal efficacy in the clinic (especially when administered to patients with solid tumors) as well as side effects such as blood thinning, cardiac abnormalities, and nausea/vomiting [28].”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“There is increasing evidence that KDAC inhibitors work best in combination with other therapies [28–30]”
From Acetylation: a new target for protein degradation in cancer (2025) · cites this paper as [28]
In the citing paper
“HDAC3 was found to be required for genome maintenance and DNA replication in hematopoietic cells (27, 28); therefore, HDAC3 inhibition is suspected to be responsible for bone marrow toxicity seen with nonselective HDAC inhibitors (29).”
From TNG260 Is a Small-Molecule CoREST Inhibitor That Sensitizes STK11 -Mutant Tumors to Anti–PD-1 Immunotherapy (2025) · cites this paper as [29]
Citations
Cites
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
New and emerging HDAC inhibitors for cancer treatment
West, A. C., & Johnstone, R. W. (2014) · Journal of Clinical Investigation · doi:10.1172/jci69738 · Cited by 1,404
Histone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Molecular and Therapeutic Potential and Toxicity of Valproic Acid
Chateauvieux, S., Morceau, F., Dicato, M., & Diederich, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/479364 · Cited by 512
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Clinical Toxicities of Histone Deacetylase Inhibitors
Subramanian, S., Bates, S. E., Wright, J. J., Espinoza-Delgado, I., & Piekarz, R. L. (2010) · Pharmaceuticals · doi:10.3390/ph3092751 · Cited by 386
Shi, Y., Dong, M., Hong, X., Zhang, W., Feng, J., Zhu, J., Yu, L., Ke, X., Huang, H., Shen, Z., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv237 · Cited by 385
Histone acetylation and disease
Timmermann, S., Lehrmann, H., Polesskaya, A., & Harel-Bellan, A. (2001) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000896 · Cited by 341
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Anti‐tumor mechanisms of valproate: A novel role for an old drug
Blaheta, R. A., & Cinatl, J. (2002) · Medicinal Research Reviews · doi:10.1002/med.10017 · Cited by 269
Valproate in the treatment of epilepsy in girls and women of childbearing potential
Tomson, T., Marson, A., Boon, P., Canevini, M. P., Covanis, A., Gaily, E., Kälviäinen, R., & Trinka, E. (2015) · Epilepsia · doi:10.1111/epi.13021 · Cited by 267
Histone deacetylase as a therapeutic target
Krämer, O. H., Göttlicher, M., & Heinzel, T. (2001) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(01)00438-6 · Cited by 257
Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia
Ceccacci, E., & Minucci, S. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.36 · Cited by 253
Vogl, D. T., Raje, N., Jagannath, S., Richardson, P., Hari, P., Orlowski, R., Supko, J. G., Tamang, D., Yang, M., Jones, S. S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2526 · Cited by 253
Prebet, T., Sun, Z., Figueroa, M. E., Ketterling, R., Melnick, A., Greenberg, P. L., Herman, J., Juckett, M., Wang, E. S., Smith, M. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.3102 · Cited by 246
Shah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
Younes, A., Berdeja, J. G., Patel, M. R., Flinn, I., Gerecitano, J. F., Neelapu, S. S., Kelly, K. R., Copeland, A. R., Akins, A., Clancy, M. S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00584-7 · Cited by 186
Histone Acetylation Modifiers in the Pathogenesis of Malignant Disease
Mahlknecht, U., & Hoelzer, D. (2000) · Molecular Medicine · doi:10.1007/bf03402044 · Cited by 180
Targeting Class I Histone Deacetylases in a “Complex” Environment
Millard, C. J., Watson, P. J., Fairall, L., & Schwabe, J. W. R. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.12.006 · Cited by 180
Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders
Pang, M., & Zhuang, S. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168385 · Cited by 173
Histone Deacetylase Inhibitors for Treating a Spectrum of Diseases Not Related to Cancer
Dinarello, C. A., Fossati, G., & Mascagni, P. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00116 · Cited by 159
Hayashi, A., Horiuchi, A., Kikuchi, N., Hayashi, T., Fuseya, C., Suzuki, A., Konishi, I., & Shiozawa, T. (2010) · International Journal of Cancer · doi:10.1002/ijc.25151 · Cited by 145
Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor
Boumber, Y., Younes, A., & Garcia-Manero, G. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.577737 · Cited by 134
Targeting Histone Deacetylases in Diseases: Where Are We?
Benedetti, R., Conte, M., & Altucci, L. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5776 · Cited by 126
HDAC Inhibitors as Novel Anti-Cancer Therapeutics
Souza, C., & Chatterji, B. (2015) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892810666150317144511 · Cited by 123
Eikel, D., Lampen, A., & Nau, H. (2006) · Chemical Research in Toxicology · doi:10.1021/tx0502241 · Cited by 123
Venugopal, B., Baird, R., Kristeleit, R. S., Plummer, R., Cowan, R., Stewart, A., Fourneau, N., Hellemans, P., Elsayed, Y., Mcclue, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0312 · Cited by 122
Ramalingam, S. S., Kummar, S., Sarantopoulos, J., Shibata, S., LoRusso, P. M., Yerk, M., Holleran, J. L., Lin, Y., Beumer, J. H., Harvey, R. D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.2307 · Cited by 113
Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N., & Rambaldi, A. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0793-8 · Cited by 109
A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma
Batlevi, C. L., Crump, M., Andreadis, C., Rizzieri, D., Assouline, S. E., Fox, S., van der Jagt, R. H. C., Copeland, A., Potvin, D., Chao, R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14698 · Cited by 107
Inhibition of Histone Deacetylase Activity by Valproic Acid Blocks Adipogenesis
Lagace, D. C., & Nachtigal, M. W. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312795200 · Cited by 106
Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104
Targeting histone deacetylases in T-cell lymphoma
Moskowitz, A. J., & Horwitz, S. M. (2017) · Leukemia & Lymphoma · doi:10.1080/10428194.2016.1247956 · Cited by 102
Ribrag, V., Kim, W. S., Bouabdallah, R., Lim, S. T., Coiffier, B., Illes, A., Lemieux, B., Dyer, M. J. S., Offner, F., Felloussi, Z., et al. (2017) · Haematologica · doi:10.3324/haematol.2016.154377 · Cited by 97
Evens, A. M., Balasubramanian, S., Vose, J. M., Harb, W., Gordon, L. I., Langdon, R., Sprague, J., Sirisawad, M., Mani, C., Yue, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0624 · Cited by 96
Effects of Ketoconazole on Glucuronidation by UDP-Glucuronosyltransferase Enzymes
Yong, W. P., Ramírez, J., Innocenti, F., & Ratain, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0703 · Cited by 73
Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead
Shah, R. R., & Stonier, P. (2018) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12759 · Cited by 68
Self-citationOptimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors
Shultz, M. D., Cao, X., Chen, C. H., Cho, Y. S., Davis, N. R., Eckman, J., Fan, J., Fekete, A., Firestone, B., Flynn, J., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200388e · Cited by 64
Action mechanisms of histone deacetylase inhibitors in the treatment of hematological malignancies
Imai, Y., Maru, Y., & Tanaka, J. (2016) · Cancer Science · doi:10.1111/cas.13062 · Cited by 63
Abaza, Y. M., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Borthakur, G., Ferrajoli, A., Estrov, Z., Wierda, W. G., Alfonso, A., Chong, T. H., et al. (2017) · Cancer · doi:10.1002/cncr.30949 · Cited by 58
Kopljar, I., Gallacher, D. J., Bondt, A. D., Cougnaud, L., Vlaminckx, E., den Wyngaert, I. V., & Lu, H. R. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0279 · Cited by 57
Brunetto, A. T., Ang, J. E., Lal, R., Olmos, D., Molife, L. R., Kristeleit, R. S., Parker, A., Casamayor, I., Olaleye, M., Mais, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0735 · Cited by 56
Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways
Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.11.004 · Cited by 55
Givinostat reduces adverse cardiac remodeling through regulating fibroblasts activation
Milan, M., Pace, V., Maiullari, F., Chirivì, M., Baci, D., Maiullari, S., Madaro, L., Maccari, S., Stati, T., Marano, G., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0174-5 · Cited by 55
Slingerland, M., Hess, D., Clive, S., Sharma, S., Sandstrom, P., Loman, N., Porro, M. G., Mu, S., Waldron, E. K., Valera, S.-Z., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2594-6 · Cited by 49
Münster, P. N., Rubin, E. H., Belle, S. V., Friedman, E. J., Patterson, J. K., Dyck, K. V., Li, X., Comisar, W. A., Chodakewitz, J., Wagner, J. A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1214 · Cited by 48
Hamberg, P., Woo, M. M., Chen, L., Verweij, J., Porro, M. G., Zhao, L., Li, W., van der Biessen, D. A. J., Sharma, S., Hengelage, T., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1693-x · Cited by 47
Schiattarella, G. G., Sannino, A., Toscano, E., Cattaneo, F., Trimarco, B., Esposito, G., & Perrino, C. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.06.012 · Cited by 47
Pharmacogenomics and Histone Deacetylase Inhibitors
Goey, A. K. L., Sissung, T. M., Peer, C. J., & Figg, W. D. (2016) · Pharmacogenomics · doi:10.2217/pgs-2016-0113 · Cited by 44
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
Sager, P. T., Balser, B., Wolfson, J., NICHOLS, J. C., Pilot, R., Jones, S. F., & Burris, H. A. (2015) · Cancer Medicine · doi:10.1002/cam4.467 · Cited by 42
Gentile, S. (2014) · CNS Spectrums · doi:10.1017/s1092852913000990 · Cited by 41
Wong, N.-S., Seah, E., Wang, L., Yeo, W.-L., Yap, H., Chuah, B., Lim, Y.-W., Ang, P., Tai, B., Lim, R., et al. (2011) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32834a8639 · Cited by 40
Lynch, D., Washam, J. B., & Newby, L. K. (2012) · Cardiology Journal · doi:10.5603/cj.2012.0078 · Cited by 39
Sharma, S., Witteveen, P. O., Lolkema, M. P., Hess, D., Gelderblom, H. A. J., Hussain, S. A., Porro, M. G., Waldron, E. K., Valera, S.-Z., & Mu, S. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2612-8 · Cited by 38
Histone Deacetylase Inhibitors Prolong Cardiac Repolarization through Transcriptional Mechanisms
Spence, S., Deurinck, M., Ju, H., Traebert, M., McLean, L., Marlowe, J. L., Emotte, C., Tritto, E., Tseng, M., Shultz, M. D., et al. (2016) · Toxicological Sciences · doi:10.1093/toxsci/kfw104 · Cited by 36
Acciavatti, T., Martinotti, G., Corbo, M., Cinosi, E., Lupi, M., Ricci, F., Scala, R. D., D’Ugo, E., Francesco, V. D., Caterina, R. D., et al. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116684337 · Cited by 30
The development and potential clinical utility of biomarkers for HDAC inhibitors
Shi, B., & Xu, W. (2013) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2013.v7.4.129 · Cited by 26
Kim, K., Park, S., Kim, J., Hong, Y. S., Lee, J., Bae, K., Cha, H., Kwon, S., Ro, S., Cho, J., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0262-2 · Cited by 23
Fischer, T. H., Patnaik, A., Bhalla, K. N., Beck, J., Morganroth, J., Laird, G., Sharma, S., Scott, J. W., Dugan, M. H., & Giles, F. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3106 · Cited by 23
Vey, N., Prébet, T., Thalamas, C., Charbonnier, A., Rey, J., Kloos, I., Liu, E., Luan, Y., Vezan, R. N., Graef, T. T., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1263843 · Cited by 22
UGT genotyping in belinostat dosing
Goey, A. K. L., & Figg, W. D. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.01.002 · Cited by 21
Restoration of mutant hERG stability by inhibition of HDAC6
Li, P., Kurata, Y., Mahati, E., Ninomiya, H., Higaki, K., Taufiq, F., Morikawa, K., Shirayoshi, Y., Horie, M., & Hisatome, I. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.01.009 · Cited by 19
A phase I study of resminostat in Japanese patients with advanced solid tumors
Kitazono, S., Fujiwara, Y., Nakamichi, S., Mizugaki, H., Nokihara, H., Yamamoto, N., Yamada, Y., Inukai, E., Nakamura, O., & Tamura, T. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2741-8 · Cited by 18
Favorable results after conservative management of 316 valproate intoxicated patients
Hassanian‐Moghaddam, H., Shadnia, S., Amırı, H., Rezai, M., Vasei, Z., Ghodrati, N., & Zamani, N. (2015) · Journal of Research in Medical Sciences · doi:10.4103/1735-1995.166211 · Cited by 15
Agarwal, N., McPherson, J. P., Bailey, H., Gupta, S. V., Werner, T. L., Reddy, G., Bhat, G., Bailey, E. B., & Sharma, S. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2934-1 · Cited by 13
Dong, D., Zhang, T., Lu, D., Liu, J., & Wu, B. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1183061 · Cited by 12
QTc prolongation and valproate toxicity
Kazim, S., Mohindra, R., Gosselin, S., & Larocque, A. (2013) · Clinical Toxicology · doi:10.3109/15563650.2013.775580 · Cited by 5
Cited by
Thirty Years of HDAC Inhibitors: 2020 Insight and Hindsight
Ho, T. C. S., Chan, A. H. Y., & Ganesan, A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00830 · Cited by 795
Recent developments of HDAC inhibitors: Emerging indications and novel molecules
Bondarev, A. D., Attwood, M. M., Jonsson, J., Chubarev, V. N., Tarasov, V. V., & Schiöth, H. B. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14889 · Cited by 416
“reason for this could be the pharmacokinetic differences between the drugs.(177) The orally available vorinostat has a short half-life (2 hours) and its time to reach peak plasma concentration is 5.”
BackgroundEpigenetic modulation and understanding of HDAC inhibitors in cancer therapy
Ramaiah, M. J., Tangutur, A. D., & Manyam, R. R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119504 · Cited by 345
Epigenetics-targeted drugs: current paradigms and future challenges
Dai, W., Qiao, X., Fang, Y., Guo, R., Bai, P., Liu, S., Li, T., Jiang, Y., Wei, S., Na, Z., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02039-0 · Cited by 339
Targeting histone deacetylases for cancer therapy: Trends and challenges
Liang, T., Wang, F., Elhassan, R. M., Cheng, Y., Tang, X., Chen, W., Fang, H., & Hou, X. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.02.007 · Cited by 222
Metadata
- Authors
- Shah, R. R.
- Corresponding author
- Shah, Rashmi R.
- ORCID
- Shah, Rashmi R.
- Venue
- Drug Safety
- Published
- 2019-01-16
- Volume
- 42
- Issue
- 2
- Pages
- 235-245
- ISSN
- 0114-5916 (ISSN-L)
- 1179-1942
- OpenAlex
- W2910383661
- Cited by
- 197
- References
- 69
- Citations by year
- 2026: 24 · 2025: 46 · 2024: 26 · 2023: 25 · 2022: 25 · 2021: 24 · 2020: 19 · 2019: 7
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Drug Safety (publishedVersion, public-domain)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- histone deacetylase inhibitors, tolerability, adverse drug reactions, myelosuppression, diarrhea, cardiotoxicity, QTc prolongation, atrial fibrillation, ventricular tachyarrhythmia, belinostat, chidamide, panobinostat, romidepsin, vorinostat, HDAC isoform selectivity, solid tumors, hematologic malignancies, T-cell lymphoma, multiple myeloma, combination therapy
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Diseases, Histone Deacetylases, Humans, Hydroxamic Acids, Neoplasms, Sulfonamides, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.